

DESCRIPTION

Species Reactivity	Mouse
Specificity	Detects mouse PLA2G2A in Western blots.
Source	Polyclonal Sheep IgG
Purification	Antigen Affinity-purified
Immunogen	<i>S. frugiperda</i> insect ovarian cell line Sf 21-derived recombinant mouse PLA2G2A Asn22-Cys146 Accession # NP_001076000
Conjugate	Alexa Fluor 350 Excitation Wavelength: 346 nm Emission Wavelength: 442 nm
Formulation	Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide
*Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.	

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Western Blot	Optimal dilution of this antibody should be experimentally determined.
Immunohistochemistry	Optimal dilution of this antibody should be experimentally determined.

PREPARATION AND STORAGE

Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied

BACKGROUND

Secretory Phospholipase A₂ is an enzyme that hydrolyses the *sn*-2 ester bond of phospholipids, generating non-esterified free fatty acids and lysophospholipids (1-3). PLA2G2A is a calcium-dependent phospholipase expressed in many cell types participating in inflammation-associated cellular responses, including platelets, neutrophils, and mast cells. It may function as an enzymatic component of the host defense mechanism. For example, human tears contain a high concentration of PLA2G2A, a principal bactericidal factor against Gram-positive bacteria in this fluid. It may play a role in cell proliferation through binding a receptor on the cell membrane. PLA2G2A has been shown to have pro-atherogenic properties both in the circulation and within the arterial wall (4). It is an acute phase protein expressed in response to a variety of pro-inflammatory cytokines. Circulating levels of sPLA2G2A are higher in coronary artery disease (CAD) patients and are associated with increased risk of future CAD (5).

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.